In 2018, Chinese researchers reported the first Phase I/II clinical trial (NCT02944162) of CD33 CAR-NK cells for the treatment of relapsed/refractory acute myeloid leukemia (AML) (94). The gene discussed is CD33; the disease is acute myeloid leukemia.